Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
36.50
-0.78 (-2.09%)
Mar 7, 2025, 4:00 PM EST - Market closed
Xenon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | - | 9.43 | 18.44 | 32.17 | Upgrade
|
| Revenue Growth (YoY) | - | - | -48.83% | -42.68% | 371.02% | Upgrade
|
| Cost of Revenue | - | 167.51 | 105.77 | 75.46 | 50.52 | Upgrade
|
| Gross Profit | - | -167.51 | -96.33 | -57.03 | -18.36 | Upgrade
|
| Selling, General & Admin | 68.9 | 46.54 | 32.81 | 21.97 | 12.94 | Upgrade
|
| Research & Development | 210.39 | - | - | - | - | Upgrade
|
| Operating Expenses | 279.3 | 46.54 | 32.81 | 21.97 | 12.94 | Upgrade
|
| Operating Income | -279.3 | -214.05 | -129.14 | -78.99 | -31.3 | Upgrade
|
| Interest Expense | - | - | - | - | -0.48 | Upgrade
|
| Interest & Investment Income | - | 27.62 | 8.71 | 0.47 | 2.28 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.2 | -1.89 | 0.36 | 1.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 40.88 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -238.42 | -186.24 | -122.32 | -78.17 | -28.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.55 | -2.93 | -0.72 | 0 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.99 | Upgrade
|
| Pretax Income | -238.42 | -182.69 | -125.26 | -78.89 | -29.09 | Upgrade
|
| Income Tax Expense | -4.09 | -0.29 | 0.12 | -0.01 | -0.26 | Upgrade
|
| Net Income | -234.33 | -182.39 | -125.37 | -78.88 | -28.84 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 0.44 | 1.8 | - | Upgrade
|
| Net Income to Common | -234.33 | -182.39 | -125.81 | -80.68 | -28.84 | Upgrade
|
| Shares Outstanding (Basic) | 78 | 67 | 61 | 44 | 36 | Upgrade
|
| Shares Outstanding (Diluted) | 78 | 67 | 61 | 44 | 36 | Upgrade
|
| Shares Change (YoY) | 16.45% | 10.48% | 38.77% | 21.09% | 23.57% | Upgrade
|
| EPS (Basic) | -3.01 | -2.73 | -2.08 | -1.85 | -0.80 | Upgrade
|
| EPS (Diluted) | -3.01 | -2.73 | -2.08 | -1.85 | -0.80 | Upgrade
|
| Free Cash Flow | - | -150.94 | -101.32 | -71.55 | -50.76 | Upgrade
|
| Free Cash Flow Per Share | - | -2.26 | -1.67 | -1.64 | -1.41 | Upgrade
|
| Gross Margin | - | - | - | - | -57.07% | Upgrade
|
| Operating Margin | - | - | -1368.91% | -428.45% | -97.31% | Upgrade
|
| Profit Margin | - | - | -1333.58% | -437.58% | -89.65% | Upgrade
|
| Free Cash Flow Margin | - | - | -1074.03% | -388.09% | -157.81% | Upgrade
|
| EBITDA | -276.73 | -210.51 | -127.52 | -78.09 | -30.66 | Upgrade
|
| EBITDA Margin | - | - | - | - | -95.31% | Upgrade
|
| D&A For EBITDA | 2.57 | 3.54 | 1.62 | 0.91 | 0.64 | Upgrade
|
| EBIT | -279.3 | -214.05 | -129.14 | -78.99 | -31.3 | Upgrade
|
| EBIT Margin | - | - | - | - | -97.31% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.